secwatch.observer — SEC 8-K summary
======================================

Issuer:     Co-Diagnostics, Inc. (CODX)
CIK:        0001692415
Form:       8-K
Filed at:   2021-08-12T23:59:59+00:00
Accession:  0001493152-21-019494
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Co-Diagnostics reports Q2 revenue of $27.4M, EPS $0.33; guides Q3 revenue $23-25M
--------------------------------------------------------------------------------

- Revenue $27.4M (+13.8% YoY); net income $9.8M ($0.33 diluted EPS) vs $15.0M ($0.51) in Q2 2020.
- Gross profit margin 90.8% ($24.9M); operating income $11.8M (-19.8% YoY) due to higher R&D and sales commissions.
- Cash and marketable securities $72.4M as of June 30; operating cash flow YTD $24.7M.
- Q3 guidance: revenue $23-25M, diluted EPS $0.19-$0.22, effective tax rate ~19%, shares ~30M.
- Over 20M tests sold to-date; CE-mark for Logix Smart Direct Saliva test; new international CoPrimer patent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1692415/000149315221019494/0001493152-21-019494-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1692415/000149315221019494/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-019494

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer